Media + Coverage

Is this mitochondria’s big moment?
9 October 2025
Longevity Technology
Read article

Lausanne based Vandria is focused on rejuvenating cells in age-related and chronic disease by inducing the removal of damaged mitochondria
6 May 2025
Biotech TV
View video

Are mitochondrial therapeutics about to go mainstream?
21 March 2025
Beyond Biotech
Listen to podcast

Distillery spotlight: new mitochondrial mechanisms from academia
12 March 2024
BioCentury
Read article [Behind Paywall]

Vandria begins clinical trials for Alzheimer’s drug VNA-318
7 January 2025
GGBA
Read news

Vandria begins clinical trials for promising mitophagy inducer
18 December 2024
Longevity Technology
Read news

European Biotech Targeting Anti-ageing
2 October 2024
Pharmatech
View article

Vandria Raises Second Series A; Round Totals $30.7M
21 August 2024
FinSMEs
Read news

Vandria closes Series A round at CHF28.3m
21 August 2024
European Biotechnology
Read news

Vandria: renewing mitochondria to treat CNS, muscle and other diseases
28 March 2024
BioCentury
Read article [Behind Paywall]

Vandria awarded €3.8M in prestigious Innosuisse and Eurostars grants
14 February 2024
BIONITY.COM
Read news

Grant will advance VNA-318 for Parkinson’s, age-related diseases
13 February 2024
Parkinson’s News Today
Read article

Vandria awarded grants to advance mitophagy drug candidates
8 February 2024
BioWorld
Read news [Behind Paywall]

Vandria launches to treat age-related diseases
5 January 2024
Chemical & Engineering News
Read news

Vandria SA Raises CHF18m for Neurodegenerative Disease Treatment
17 December 2023
BioProcess Updates
Read news

Vandria raises USD 20.6M and emerges from stealth
15 December 2023
Startup ticker.ch
Read news

Vandria emerges from stealth with $20.6m and clinic-ready lead candidate
14 December 2023
Longevity Technology
Read news